For a Limited Time: Get 3 Years of Access at the Price of 1
Here is the latest financial fact sheet of BETA DRUGS . For more details, see the BETA DRUGS quarterly results and BETA DRUGS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -0.9 |
No. of shares | m | 9.61 |
1 Week | % | -8.1 |
1 Month | % | -3.4 |
1 Year | % | 80.2 |
52 week H/L | Rs | 1,595.0/660.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
BETA DRUGS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 140 | 124 | 141 | 695 | 1,024 | |
Low | Rs | 57 | 37 | 39 | 119 | 546 | |
Sales per share (Unadj.) | Rs | 76.2 | 94.5 | 120.8 | 191.3 | 236.3 | |
Earnings per share (Unadj.) | Rs | 9.3 | 9.8 | 12.2 | 25.8 | 32.0 | |
Diluted earnings per share | Rs | 8.4 | 9.8 | 12.2 | 25.8 | 32.0 | |
Cash flow per share (Unadj.) | Rs | 12.6 | 13.7 | 19.4 | 33.4 | 42.8 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 47.3 | 59.4 | 71.4 | 96.1 | 127.9 | |
Adj. book value per share | Rs | 42.6 | 59.4 | 71.4 | 96.1 | 127.8 | |
Shares outstanding (eoy) | m | 8.65 | 9.61 | 9.61 | 9.61 | 9.61 | |
Price / Sales ratio | x | 1.3 | 0.9 | 0.7 | 2.1 | 3.3 | |
Avg P/E ratio | x | 10.6 | 8.2 | 7.4 | 15.8 | 24.6 | |
P/CF ratio (eoy) | x | 7.8 | 5.9 | 4.6 | 12.2 | 18.4 | |
Price / Book Value ratio | x | 2.1 | 1.4 | 1.3 | 4.2 | 6.1 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 852 | 774 | 864 | 3,913 | 7,549 | |
Total wages/salary | Rs m | 38 | 69 | 83 | 121 | 171 |
BETA DRUGS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 659 | 908 | 1,161 | 1,838 | 2,271 | |
Other income | Rs m | 4 | 4 | 5 | 8 | 8 | |
Total revenues | Rs m | 663 | 912 | 1,166 | 1,846 | 2,279 | |
Gross profit | Rs m | 118 | 179 | 247 | 427 | 531 | |
Depreciation | Rs m | 28 | 38 | 69 | 73 | 104 | |
Interest | Rs m | 14 | 26 | 24 | 19 | 24 | |
Profit before tax | Rs m | 79 | 120 | 160 | 343 | 411 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | -1 | 26 | 42 | 95 | 103 | |
Profit after tax | Rs m | 80 | 94 | 117 | 248 | 307 | |
Gross profit margin | % | 17.9 | 19.7 | 21.3 | 23.2 | 23.4 | |
Effective tax rate | % | -1.7 | 21.4 | 26.5 | 27.6 | 25.2 | |
Net profit margin | % | 12.2 | 10.4 | 10.1 | 13.5 | 13.5 |
BETA DRUGS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 439 | 573 | 713 | 1,028 | 1,344 | |
Current liabilities | Rs m | 334 | 380 | 366 | 548 | 697 | |
Net working cap to sales | % | 16.0 | 21.3 | 29.9 | 26.1 | 28.5 | |
Current ratio | x | 1.3 | 1.5 | 1.9 | 1.9 | 1.9 | |
Inventory Days | Days | 39 | 28 | 19 | 10 | 11 | |
Debtors Days | Days | 138,563,968 | 128,331,851 | 1,065 | 897 | 1,008 | |
Net fixed assets | Rs m | 394 | 510 | 488 | 602 | 695 | |
Share capital | Rs m | 87 | 96 | 96 | 96 | 96 | |
"Free" reserves | Rs m | 323 | 475 | 590 | 827 | 1,133 | |
Net worth | Rs m | 409 | 571 | 686 | 923 | 1,229 | |
Long term debt | Rs m | 69 | 103 | 111 | 118 | 70 | |
Total assets | Rs m | 834 | 1,083 | 1,201 | 1,630 | 2,039 | |
Interest coverage | x | 6.5 | 5.6 | 7.6 | 19.1 | 18.0 | |
Debt to equity ratio | x | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | |
Sales to assets ratio | x | 0.8 | 0.8 | 1.0 | 1.1 | 1.1 | |
Return on assets | % | 11.4 | 11.1 | 11.8 | 16.4 | 16.2 | |
Return on equity | % | 19.6 | 16.5 | 17.1 | 26.9 | 25.0 | |
Return on capital | % | 19.5 | 21.6 | 23.0 | 34.8 | 33.5 | |
Exports to sales | % | 7.4 | 3.6 | 10.2 | 8.3 | 12.3 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0.2 | |
Exports (fob) | Rs m | 49 | 32 | 118 | 152 | 278 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 5 | |
Fx inflow | Rs m | 49 | 32 | 118 | 152 | 278 | |
Fx outflow | Rs m | 5 | 6 | 3 | 5 | 48 | |
Net fx | Rs m | 44 | 26 | 116 | 147 | 231 |
BETA DRUGS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1 | 84 | 186 | 296 | 234 | |
From Investments | Rs m | -208 | -151 | -58 | -218 | -191 | |
From Financial Activity | Rs m | 121 | 87 | -77 | -10 | -25 | |
Net Cashflow | Rs m | -86 | 21 | 50 | 69 | 18 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Rahul Batra | COMP SEC: Rajni Brar | YEAR OF INC: 2005 | NSE CODE: 99111114 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare BETA DRUGS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.